BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36238279)

  • 21. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma.
    Qian L; Lai X; Gu B; Sun X
    Front Immunol; 2022; 13():784479. PubMed ID: 35603163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 25. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Zheng Z; Wang X; Huang Y; Lu X; Chi P
    Colorectal Dis; 2020 Dec; 22(12):2068-2077. PubMed ID: 32936987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade.
    Mei J; Cai Y; Xu R; Li Q; Chu J; Luo Z; Sun Y; Shi Y; Xu J; Li D; Liang S; Jiang Y; Liu J; Qian Z; Zhou J; Wan M; Yang Y; Zhu Y; Zhang Y; Yin Y
    Cancer Commun (Lond); 2024 May; 44(5):554-575. PubMed ID: 38507505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis.
    Tochigi T; Kamran SC; Parakh A; Noda Y; Ganeshan B; Blaszkowsky LS; Ryan DP; Allen JN; Berger DL; Wo JY; Hong TS; Kambadakone A
    Eur Radiol; 2022 Apr; 32(4):2426-2436. PubMed ID: 34643781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
    Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
    J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances in the prediction of the efficacy and sensitivity of neoadjuvant chemoradiotherapy in rectal cancer].
    Ji Q; Li YF; Wu T
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):392-397. PubMed ID: 31054555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer.
    He F; Yu L; Ding Y; Li ZH; Wang J; Zheng J; Chen HY; Liu S; Pang XL; Ajani JA; Wan XB
    Cancer Sci; 2020 Nov; 111(11):4205-4217. PubMed ID: 32860448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 34. An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.
    D'Angelo E; Pastrello C; Biccari A; Marangio A; Sensi F; Crotti S; Fassan M; Jurisica I; Pucciarelli S; Agostini M
    Int J Cancer; 2023 Jul; 153(2):437-449. PubMed ID: 36815540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
    Wang Y; Chen L; Ju L; Xiao Y; Wang X
    Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
    Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
    Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The value of MR T2WI signal intensity related parameters for predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer].
    Wan LJ; Zhang CD; Zhang HM; Meng YK; Ye F; Liu Y; Zhao XM; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):837-843. PubMed ID: 31770851
    [No Abstract]   [Full Text] [Related]  

  • 38. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance.
    Liu H; Wang H; Wu J; Wang Y; Zhao L; Li G; Zhou M
    Radiother Oncol; 2019 Feb; 131():52-59. PubMed ID: 30773187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker.
    Kim S; Yeo MK; Kim JS; Kim JY; Kim KH
    J Cancer; 2022; 13(1):162-173. PubMed ID: 34976180
    [No Abstract]   [Full Text] [Related]  

  • 40. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.